Telix Pharmaceuticals Limited
55 Flemington Road
About Telix Pharmaceuticals Limited
A clinical-stage biotechnology company dedicated to the development and commercialisation of molecurlarly-targeted radiation (MTR) therapy.
33 articles with Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited announces that the Australian Therapeutic Goods Administration has approved Illuccix®, the Company’s lead prostate cancer imaging product.
10/25/2021It was yet another busy week for clinical trial news. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
Telix Pharmaceuticals Limited is pleased to announce the first set of peer-reviewed results from the IPAX-1 Ph I/II study of TLX101 in combination with external beam radiation therapy in recurrent glioblastoma multiforme has been delivered as a late breaking oral presentation at the Congress of Neurological Surgeons Annual Meeting currently taking place in Austin, Texas.
Modern radiation therapy is tightly targeted to dramatically reduce toxicity and side effects and often can be administered on an outpatient basis.
10/11/2021Another busy week for clinical trial news. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Telix Pharmaceuticals Limited has welcomed the Society of Nuclear Medicine and Molecular Imaging updated Appropriate Use Criteria for prostate specific membrane antigen positron emission tomography imaging.
Biopharma and life sciences companies and organizations from across the globe provide updates on their businesses and pipelines.
Telix Pharmaceuticals Limited has welcomed the updated National Comprehensive Cancer Network® Guidelines® for prostate cancer,1 which includes prostate specific membrane antigen positron emission tomography imaging modalities, including Ga-68 PSMA-11.
Telix Pharmaceuticals Limited announces that it has entered into an exclusive licence agreement for a novel positron emission tomography radiotracer that originates from the Université catholique de Louvain.
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has commenced a collaboration with Kettering Health (KH), a faith-based network of 13 hospitals, emergency centers, and outpatient facilities located in Southwest Ohio; headquartered at the Kettering Memorial Hospital in Kettering, Ohio, United States.
Telix Pharmaceuticals Limited announces the initiation of two new investigator-led studies to evaluate the potential utility of the Company’s late-stage imaging portfolio in women’s health, initially in two sub-types of breast cancer with a significant unmet medical need.
Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
Telix Pharmaceuticals Limited today announced the launch of TelixU , a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied Radiology .
Telix Pharmaceuticals Limited announces that Chief Executive Officer, Dr. Christian Behrenbruch, will present at the Jefferies Virtual Healthcare Conference 2021.
Cardinal Health and Telix Launch Gallium Awareness Campaign With Release of White-Paper: “Moving Beyond the Myth”
As interest and demand for more accurate prostate cancer imaging grows, and with the approval of the first Ga-68 PSMA based prostate imaging agent late last year1, Cardinal Health Nuclear & Precision Health Solutions and Telix Pharmaceuticals Inc. have developed an in-depth white-paper, entitled: “Moving beyond the Myth: Meeting the growing demand for Ga-68 radiopharmaceuticals.”
Telix Pharmaceuticals Limited announces it has been granted Human Research Ethics Committee approval and received Clinical Trial Notification clearance by the Australian Therapeutic Goods Administration to commence a Phase III clinical trial of the Company’s PSMA1 targeted prostate cancer therapy candidate TLX591, in patients with advanced metastatic castrate-resistant prostate cancer.
ITM Enters Global Supply Agreements with Telix Pharmaceuticals for Clinical and Commercial Use of ITM’s n.c.a. Lutetium-177
ITM AG, a privately held radiopharmaceutical biotech company, announced that is has signed two strategic agreements with Telix Pharmaceuticals Limited for the global supply of ITM’s highly pure therapeutic radioisotope no-carrier-added Lutetium-177.
Telix Pharmaceuticals Limited announces that the first patients have been dosed in the Phase III ZIRCON1 clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx in the United States.
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance” The IRiS Alliance is an exclusive scientific and clinical research collaboration that combines two highly complementary technologies to deliver greater precision in the diagnosis and surgical management of urological cancers.